Regeneron Pharmaceuticals (REGN) Cost of Revenue (2009 - 2026)

Regeneron Pharmaceuticals has reported Cost of Revenue for 18 years, with the latest figure at $360.7 million in Q2 2026.

• On a quarterly basis, Cost of Revenue rose 30.88% year-over-year to $360.7 million in Q2 2026; TTM through Jun 2026 was $1.3 billion, a 18.01% increase from a year earlier, with the FY2025 full-year figure at $1.1 billion, up 4.92% from the prior year.
• Cost of Revenue was $360.7 million for Q2 2026 at Regeneron Pharmaceuticals, down from $373.4 million in the prior quarter.
• The five-year high for Cost of Revenue was $373.4 million in Q1 2026, with the low at $149.2 million in Q2 2022.
• Average Cost of Revenue over 5 years is $262.1 million, with a median of $260.4 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2023: Cost of Revenue plunged 72.34% in 2022, then soared 42.43% in 2023.
• Over 5 years, Cost of Revenue stood at $278.0 million in 2022, then dropped by 6.98% to $258.6 million in 2023, then rose by 26.37% to $326.8 million in 2024, then decreased by 2.48% to $318.7 million in 2025, then grew by 13.18% to $360.7 million in 2026.
• The last three Cost of Revenue figures came in at $360.7 million (Q2 2026), $373.4 million (Q1 2026), and $318.7 million (Q4 2025), per Business Quant data.